Meeting
2022 ASCO Genitourinary Cancers Symposium
PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.
Authors
Giulio Francolini
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
Giulio Francolini , Mauro Loi , Lucia Pia Ciccone , Monica Mangoni , Beatrice Detti , Vanessa Di Cataldo , Michele Aquilano , Andrea Allegra , Pamela Pinzani , Francesca Salvianti , Cecilia Cerbai , Luca Burchini , Giulio Frosini , Chiara Mattioli , Viola Salvestrini , Barbara Guerrieri , Giulia Salvatore , Mariangela Sottili , Isacco Desideri , Lorenzo Livi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04188275
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 137)
DOI
10.1200/JCO.2022.40.6_suppl.137
Abstract #
137
Poster Bd #
G11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2017 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.
First Author: Amy K Taylor
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang